STSA — Satsuma Pharmaceuticals Share News
0.000.00%
Last trade - 00:00HealthcareSpeculativeMicro Cap
Satsuma Pharma surges; co announces results of clinical trial
Satsuma Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary
Brief: Satsuma Pharmaceuticals Reports First Quarter 2021 Financial Results And Recent Business Highlights
Satsuma Pharmaceuticals Inc expected to post a loss of 42 cents a share - Earnings Preview
Brief: Satsuma Says Selling Securityholders May Offer Up To 14.1 Million Shares
Satsuma Pharma: Jumps on plan to start new phase 3 trial for migraine treatment
Brief: Satsuma Pharmaceuticals Announces $80 Mln Private Placement Financing
Brief: Satsuma Says New Phase 3 Trial For Migraine Product Candidate To Begin Mid-2021
Brief: Satsuma Pharmaceuticals Files For Mixed Shelf Of Up To $150 Mln
Satsuma Pharma: Credit Suisse double downgrades, lowest PT in Street
U.S. RESEARCH ROUNDUP-Lyondellbasell Industries, Navistar International, Oracle
Brief: Satsuma Pharmaceuticals Announces Topline Results From Emerge Phase 3 Trial Of Sts101 For The Acute Treatment Of Migraine
Satsuma: Slumps as migraine therapy late-stage study goals not met
Brief: Satsuma Pharmaceuticals Posts Q2 Loss Per Share Of $0.65
Brief: Satsuma Pharmaceuticals Announces Enrollment Of First Patient In The Ascend™ Phase 3 Open-Label, Safety Trial Of Sts101
Brief: Satsuma Completes Enrollment In Pivotal Phase 3 Emerge Trial Of STS101 For Acute Treatment Of Migraine
Brief: Satsuma Pharmaceuticals Q1 Loss Per Share $0.68
U.S. STOCKS ON THE MOVE-Sonos, Estee Lauder, PPD, ForeScout Tech, Twitter
U.S. STOCKS ON THE MOVE-Lannett, Vista Outdoor, Twitter, iRobot, Zynga